b
Thank You！
Your requirement has been sent, we will contact you quickly!
Sent Failed！
Try again!
Product introduction:
Ticagrelor is a new antiplatelet agglutination drug. It is the first reversible binding oral P2Y12 adenosine diphosphate receptor antagonist in the world. It can reversibly act on purinoceptor2 (P2) subtype P2Y12 on vascular smooth muscle cells (VSMC), does not need metabolic activation, and has a significant inhibitory effect on platelet aggregation caused by adenosine diphosphate (ADP), After oral use, it takes effect quickly and can effectively improve the symptoms of patients with acute coronary heart disease. Unlike thiophenopyridine drugs, ticagrel is a reversible inhibitor of P2Y12 receptor, so it is especially suitable for patients who need to undergo surgery after early anticoagulant treatment.
CAS：274693-27-5
Molecular formula: C23H28F2N6O4S
Molecular weight: 522.57
Structural type: 
Chemical property: white to beige solid
Product purpose: Anticoagulants; It is used to reduce cardiovascular death and heart attack in patients with acute coronary syndrome (ACS)
Manufacturing
